Base Editing (BE) Efficiency Detection

Base Editing (BE) Efficiency Detection

1. Background

Base editors (BEs), as a pivotal representative of third-generation gene editing technologies, have demonstrated transformative potential in the fields of precision medicine and genetic disease therapy. In contrast to conventional CRISPR-Cas9 technology, base editing does not require the introduction of double-strand breaks (DSBs), enabling precise C→T or A→G transitions at the single-nucleotide level. This substantially reduces the risk of insertion-deletion mutations (indels) and chromosomal rearrangements, offering a safer and more efficacious therapeutic strategy for diseases caused by single-nucleotide variants.

Two principal classes of base editors are currently in clinical application: cytosine base editors (CBEs) and adenine base editors (ABEs). CBEs catalyze the deamination-mediated conversion of C·G base pairs to T·A, and have entered clinical trial phases for the treatment of hematological disorders including β-thalassemia and sickle cell disease. ABEs, by contrast, mediate precise A·T to G·C conversions and have demonstrated considerable therapeutic promise in hereditary metabolic diseases and neurodegenerative conditions. To date, more than 20 clinical trials employing base editing technologies have received regulatory approval worldwide, marking a critical transition from bench-top research to clinical translation.

In recent years, regulatory authorities worldwide—including the U.S. Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) of China—have imposed comprehensive and stringent requirements for the safety assessment of gene editing products. These requirements specifically address off-target effects, chromosomal structural variants, vector integration risks, and the residual presence of editing machinery. The FDA guidance document entitled Human Gene Therapy Products Incorporating Human Genome Editing, issued in January 2024, explicitly mandates comprehensive off-target risk assessments for gene editing products, emphasizing the integrated application of bioinformatics, biochemical, and cellular methodologies for genome-wide analyses. It further requires systematic evaluation of chromosomal integrity, clonal expansion risks, and the biological consequences of editing products (Figure 1).

Figure 1. Core safety assessment requirements for gene editing products as stipulated in the FDA guidance: Human Gene Therapy Products Incorporating Human Genome Editing

Nevertheless, conventional PCR-based Sanger sequencing methods exhibit limited sensitivity (limit of detection: approximately 10%–20%), rendering them inadequate for accurate quantification of low-frequency editing events. Furthermore, their low throughput and inability to comprehensively survey multi-site nucleotide changes within the editing window preclude their application in the precise evaluation required by current regulatory frameworks. To address these analytical limitations, Generulor has developed a specialized on-target amplicon sequencing platform based on next-generation sequencing (NGS). This platform employs target-specific amplification primers flanking the base editing locus, followed by ultra-deep sequencing, enabling comprehensive and precise characterization of on-target editing efficiency and the full spectrum of editing product distributions—thereby providing reliable data support for quality control and IND submissions of base editing therapeutics.

2. Principles of Base Editing Efficiency Detection

The on-target amplicon sequencing technology for base editing leverages the high-throughput and high-sensitivity attributes of next-generation sequencing (NGS), integrated with an optimized experimental workflow and a bioinformatics analysis pipeline specifically tailored to the characteristics of base editing. This technology involves the specific amplification of genomic regions flanking the target editing site (typically 150–280 bp), followed by ultra-deep sequencing (≥1,000,000×) to achieve precise quantitative analysis of editing outcomes.

The analytical workflow encompasses the following steps: (i) design of highly specific amplification primers based on the sgRNA sequence of the base editor, enabling accurate amplification of the target region encompassing the editing window; (ii) library construction and high-depth sequencing to ensure detection of editing events at frequencies as low as 0.1%; and (iii) application of a purpose-built bioinformatics analysis pipeline that not only accurately identifies the expected C→T or A→G transitions, but also comprehensively detects all nucleotide changes within and beyond the editing window, insertion-deletion mutations, and potential bystander editing events.

Compared to conventional detection methods, this technology platform offers three cardinal advantages: (1) Ultra-high sensitivity—with a limit of detection of 0.1%, enabling the identification of extremely low-frequency editing events and potential off-target effects; (2) Comprehensive analysis—encompassing not only the quantification of intended base conversion efficiency, but also systematic assessment of the frequency and distribution patterns of unintended editing products (e.g., indels, substitutions, and bystander edits); (3) High-throughput capacity—supporting the simultaneous analysis of hundreds of samples and multiple target sites in a single experimental run, substantially enhancing research and development efficiency while reducing cost.

Figure 2. Schematic Diagram of the BE Base Editing Efficiency Detection Workflow.

3. Technical Innovations and Advantages of the BE Base Editing Efficiency Detection Platform

3.1 Core Technical Innovations

3.1.1 Base Editing–Specific Primer Design Strategy

A specialized primer design algorithm has been developed in accordance with the mechanistic features of base editors, encompassing the following design principles:

(1) Precise coverage of the editing window (typically positions 1–20 upstream of the sgRNA target sequence), ensuring comprehensive capture of all potential base conversion events.

(2) Extension 50–100 bp beyond the editing window to detect off-window off-target editing and bystander effects.

(3) Optimization of primer sequences to avoid known SNP loci, preventing interference from polymorphisms in editing efficiency assessment.

(4) Implementation of a paired-end sequencing strategy to ensure that editing sites are positioned in the central region of sequencing reads, thereby maximizing nucleotide identification accuracy.

3.1.2 Ultra-Deep Sequencing and Quality Control Framework

Stringent quality control standards have been established for sequencing depth and overall data quality:

(1) Effective sequencing depth ≥1,000,000×, ensuring statistically reliable detection of editing events occurring at frequencies as low as 0.1%.

(2) Q30 base quality score fraction ≥85%, guaranteeing accuracy in single-nucleotide variant identification.

(3) Multiple negative controls (unedited samples and sgRNA-free controls) to characterize background mutation levels.

3.1.3 Base Editing–Specific Bioinformatics Analysis

A professional bioinformatics analysis pipeline has been integrated to accomplish the following analytical objectives:

(1) Precise discrimination between expected base conversions (C→T or A→G) and unintended mutations (alternative substitutions, indels, etc.).

(2) Quantitative analysis of editing efficiency distributions across multiple C (or A) positions within the editing window, enabling identification of editing preference patterns.

(3) Generation of editing pattern visualization heatmaps, providing an intuitive representation of the site-specific distribution of editing outcomes.

3.2 Methodological Validation and Performance Metrics

Generulor has completed a comprehensive and systematic methodological validation. The technical performance metrics are summarized in the following table:

4. Applications and Service Advantages

4.1 Application Scenarios

The on-target amplicon sequencing technology for ABE/CBE base editing encompasses broad applications across the entire continuum of gene editing therapeutic product development and regulatory evaluation:

(1) Base editor screening and optimization: Comparative evaluation of editing efficiency, editing window preference, and by-product rates among different base editor variants (e.g., BE3, BE4max, ABE8e), to guide selection of the optimal editing tool.

(2) sgRNA design validation: Systematic evaluation of editing efficiency and precision for candidate sgRNAs to identify optimal target sequences for downstream product development.

(3) Process development and quality control: Monitoring the impact of different delivery systems (AAV, LNP, electroporation, etc.) on editing efficiency, and optimization of cell culture and editing conditions.

(4) IND submission support: Provision of on-target editing efficiency data and methodological validation reports compliant with regulatory requirements, supporting clinical trial applications.

(5) Preclinical safety evaluation: Assessment of editing efficiency and unintended mutation frequencies in animal models and organoid systems, providing data for clinical risk assessment.

(6) Clinical sample monitoring: Detection of editing efficiency and persistence in patient-derived samples to support evaluation of clinical efficacy and safety.

4.2 Service Advantages

(1) Technical leadership: An assay platform optimized specifically for the unique characteristics of base editing, offering superior accuracy and informational completeness relative to generic NGS methods.

(2) Certified quality management system: The laboratory simultaneously operates under the ISO 9001 quality management system and CNAS accreditation standards for testing laboratories, ensuring data reliability and regulatory traceability.

(3) Comprehensive methodological validation: Full validation covering sensitivity, specificity, accuracy, linearity, and precision has been completed; validation reports are directly applicable to IND submissions.

(4) Standardized reporting: Analytical reports are fully compliant with the latest guidance documents from NMPA-CDE and FDA, supporting regulatory submissions and inspections.

(5) Expert technical support: A technical team with extensive experience in gene editing product development and regulatory submissions, providing end-to-end consulting services from experimental design through data interpretation.

(6) Proven track record: Established base editing detection services for multiple leading gene therapy companies and research institutions, with successful support for multiple IND submission projects.

5. Representative Report Examples for BE Base Editing Efficiency Detection

Generulor provides comprehensive on-target base editing analytical reports compliant with regulatory requirements, encompassing detailed sequencing data quality assessment and quantitative analysis of base editing efficiency. In addition, reports include the following core components:

(1) Sequencing data quality and alignment statistics: The report provides a detailed assessment of sequencing data quality, including the number of clean reads and clean ratio following raw data filtration, the paired-end read merging efficiency (merge ratio), and the amplicon reference sequence alignment efficiency (align ratio). These metrics comprehensively reflect library quality and sequencing data reliability, ensuring that subsequent base editing efficiency analyses are grounded in high-quality data.

Figure 3. Summary table of read merging and alignment statistics (representative example).

(2) Quantitative analysis of base editing efficiency: Employing the CRISPResso2 software framework, sequencing reads are aligned to reference sequences to enumerate the number of modified reads (Modified read counts) and calculate editing efficiency (Modified rate) in both experimental and control groups. The report simultaneously outputs editing efficiency data both prior to (Raw) and following (Filtered) quality filtration; background noise is removed by computing the differential between experimental and control groups, enabling precise quantification of on-target base editing efficiency.

Figure 4. Gene editing efficiency summary table (representative example).

(3) Classification of editing events: All detected editing events are subjected to fine-grained classification by mutation type, with separate enumeration of frequencies for sole insertions (Only Ins), sole deletions (Only Del), sole substitutions (Only Sub), and various complex editing combinations, along with aggregated InDel rates. In accordance with the specific features of base editors, the report further quantifies the conversion efficiency of each target base position within the editing window, as well as bystander editing events—including A→G conversions for ABE and C→T conversions for CBE—providing granular data for the assessment of editing precision and specificity.

Figure 5. Editing classification summary table (representative example).

(4) Visualization of editing product sequences: All high-frequency editing events within the editing locus region (constituting >0.2% of total reads) are displayed at single-nucleotide resolution. The first row depicts the unedited reference amplicon sequence; subsequent rows represent the spectrum of detected editing sequences. The four nucleotides are distinguished by color; substituted positions are marked in bold font, providing an intuitive visualization of the base transition landscape within the editing window and associated bystander editing patterns. The right-hand panel displays, in sequential order, the experimental group read proportion, experimental group read count, control group read proportion, and control group read count—providing direct sequence-level evidence for editing window analysis and specificity assessment.

Figure 6. Editing product visualization (representative example).

6. Service Content for BE Base Editing Efficiency Detection

*Standard turnaround time: 20–30 business days.

7. Sample Requirements

*Note: ① All samples must meet the above quality standards to ensure the accuracy and reliability of detection results. ② Clients may also submit tissue or cell pellet samples for DNA extraction; tissue samples require a minimum weight of >50 mg, and cell pellets require >2×10⁷ cells per target site. ③ For special sample types, please contact the Generulor technical team in advance (Tel: 400-6309596; Product orders/Technical support: service@generulor.com).

8. References

[1] Gaudelli, N. M., et al. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature, 551(7681), 464-471.

[2] Komor, A. C., et al. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420-424.

[3] Koblan, L. W., et al. (2021). In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature, 589(7843), 608-614.

[4] 国家药品监督管理局药品审评中心. 体内基因治疗产品药学研究与评价技术指导原则(试行)[EB/OL]. 北京: 国家药品监督管理局药品审评中心, 2022-05.

[5] 国家药品监督管理局药品审评中心. 体外基因修饰系统药学研究与评价技术指导原则(试行)[EB/OL]. 北京: 国家药品监督管理局药品审评中心, 2022-05.

[6] 国家药品监督管理局药品审评中心. 基因修饰细胞治疗产品非临床研究技术指导原则(试行)[EB/OL]. 北京: 国家药品监督管理局药品审评中心, 2021-11.

[7] U.S. Food and Drug Administration. Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry [EB/OL]. Silver Spring, MD: FDA, January 2024.